concept

TAU HYPERPHOSPHORYLATION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAU HYPERPHOSPHORYLATION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

54Connections

0Hypotheses

1Analyses

16Outgoing

38Incoming

0Experiments

2Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	TAU HYPERPHOSPHORYLATION

Pathway Diagram

graph TD
    TAU_HYPERPHOSPHORYLATION["TAU HYPERPHOSPHORYLATION"]
    TAU_HYPERPHOSPHORYLATION -->|"contributes to"| Tau_Aggregation["Tau Aggregation"]
    TAU_HYPERPHOSPHORYLATION -->|"causes"| Alzheimer_s_disease["Alzheimer's disease"]
    MAPT["MAPT"] -->|"involved_in"| TAU_HYPERPHOSPHORYLATION
    Exendin_4["Exendin-4"] -->|"inhibits"| TAU_HYPERPHOSPHORYLATION
    ASK1["ASK1"] -->|"causes"| TAU_HYPERPHOSPHORYLATION
    Wnt___catenin_NeuroD1_Pathway["Wnt/beta-catenin/NeuroD1 Pathway"] -->|"regulates"| TAU_HYPERPHOSPHORYLATION
    Neuroinflammation["Neuroinflammation"] -->|"contributes to"| TAU_HYPERPHOSPHORYLATION
    HEPATOKINES["HEPATOKINES"] -->|"regulates"| TAU_HYPERPHOSPHORYLATION

Outgoing (16)

Target	Relation	Type	Str
Neurofibrillary Tangles	causes	biomarker	0.95
Alzheimer's Disease	associated_with	disease	0.95
Alzheimer'S Disease	biomarker_for	disease	0.90
Tauopathies	biomarker_for	disease	0.90
Alzheimer's Disease	drives	disease	0.90
Neurodegeneration	contributes_to	process	0.90
Paired Helical Filaments	causes	biomarker	0.90
Synaptic Toxicity	associated_with	phenotype	0.90
Cognitive Impairments	associated_with	phenotype	0.90
tau O-GlcNAc protection	suppresses	process	0.85
Tau Aggregation	contributes_to	process	0.85
Type 2 Diabetes	associated_with	disease	0.85
Alzheimer'S Disease	contributes_to	disease	0.85
Alzheimer's disease	associated_with	disease	0.70
Alzheimer's disease	causes	disease	0.70
Alzheimer's disease	causes	disease	0.70

Incoming (38)

Source	Relation	Type	Str
DAB	causes	compound	0.95
MAPT	involved_in	protein	0.95
GSK3B	involved_in	gene	0.95
PPP2CA	regulates	gene	0.95
Aβ oligomers	triggers	biomarker	0.90
Ampk Activation	promotes	process	0.90
MAPT MUTATION	causes	gene	0.90
Air Pollution	causes	compound	0.90
Sulforaphane	inhibits	compound	0.90
Exendin-4	inhibits	drug	0.90
PKR	causes	entity	0.90
Wnt/β-catenin/NeuroD1 Pathway	regulates	pathway	0.85
ASK1	mediates	protein	0.85
Tau Kinase Inhibitors	inhibits	drug	0.85
Platelets	associated_with	cell_type	0.85
MTOR	promotes	gene	0.85
ASK1	causes	protein	0.85
Ceramide	contributes_to	compound	0.85
APOE4	risk_factor_for	gene	0.85
GSK3B	mediates	gene	0.80
ASK1	contributes_to	protein	0.80
miR-132	inhibits	biomarker	0.80
HEPATOKINES	regulates	protein	0.80
miR-125b	contributes_to	biomarker	0.80
Insulin Signaling	inhibits	pathway	0.80
Neuroinflammation	contributes_to	process	0.80
BACE1	causes	gene	0.70
Ramalin	suppresses	gene	0.70
Indoles	protects_against	process	0.70
BMAL1	protects_against	gene	0.70
Exendin-4	inhibits	drug	0.70
GSK3β	activates	protein	0.70
GSK-3	regulates	protein	0.70
PI3K	inhibits	gene	0.70
mTOR	activates	protein	0.70
MTOR	activates	protein	0.70
SLC1A2	contributes_to	gene	0.60
AKT	regulates	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning TAU HYPERPHOSPHORYLATION in their description or question text

No additional research found